AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 252 min read$RAPP

Rapport Therapeutics’ RAP-219 Hits Phase II Goals in Bipolar Mania Trial

Rapport Therapeutics (NASDAQ: RAPP) announced positive Phase II trial results for RAP-219 in bipolar mania, with plans to advance to Phase III. The drug was well-tolerated, with mild to moderate adverse events. The company aims to meet with the FDA in Q1 2027 and start Phase III trials in the second half of 2027. Rapport also expects to report long-term safety data for RAP-219 in focal onset seizures in Q4 2026.

Original reporting
finance.yahoo.com
Published Oct 25, 2026, 5:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 25, 2026, 5:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Rapport Therapeutics’ RAP-219 Hits Phase II Goals in Bipolar Mania Trial — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$RAPPBullishMed
01

Why it matters

The new bipolar mania data expands the drug's potential indications, supporting a larger market opportunity and possibly accelerating the path to Phase III.

02

Market read

Positive trial data for a small‑cap biotech can trigger a notable price move, especially ahead of upcoming FDA meetings.

03

What to watch

Potential regulatory delays and competition from other CNS therapeutics could temper upside.

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

Rapport Therapeutics (NASDAQ:RAPP) is a clinical‑stage biotech developing RAP‑219 for CNS disorders. The company previously reported Phase II data in focal onset seizures.

Company-level read

Ticker impact

$RAPPBullishHigh confidence
Context

Rapport Therapeutics reported Phase II success for RAP-219 in bipolar mania, a first disclosure of these trial results.

Expected impact

likely upward pressure as market prices in the favorable trial outcome

Evidence & confidence

First report of pivotal trial data; biotech stocks typically react strongly to positive Phase II results.

Market effects

Sector

May lift sentiment for CNS‑focused biotech sector and encourage funding for similar programs.

Regional

Limited to U.S. biotech investors; no broader regional effect.

Global

Modest global relevance, primarily affecting biotech‑focused funds.

Counterpoint

What could challenge this read

If the Phase III plan stalls or data fails to translate, the rally could be short‑lived.

Key entities

  • Executive
    Abe Ceesay

    Chief Executive Officer of Rapport Therapeutics

  • Executive
    Troy Ignelzi

    Chief Financial Officer of Rapport Therapeutics

Read at source← All news

Related articles

OCT 21
$RAPPMed

Jones Trading raises Rapport Therapeutics price target on pipeline potential

Jones Trading raised its price target for Rapport Therapeutics (RAPP) to $82 from $50, maintaining a Buy rating. The firm cited positive clinical trial results for the company’s RAP-219 drug candidate in FOS and BPM indications. The stock currently trades at $29.37, giving the company a market capitalization of $1.41 billion. Analysts have varied price targets and ratings for RAPP, with a consensus Strong Buy rating.

investing.com1 min
OCT 20
$RAPPHigh

RAPP Stock Tempers Premarket Gains On Concerns Over Higher Discontinuation Rates In Bipolar Mania Study

RAPP stock initially rose but later tempered gains due to concerns over higher discontinuation rates in a bipolar mania study. Analysts at H.C. Wainwright and Raymond James raised their price targets to $66 and $86 respectively, while Wells Fargo maintained an Overweight rating with a $51 target. Retail traders on Stocktwits reacted bullishly, with some suggesting the company is a potential buyout candidate. The stock is down 3% year-to-date.

finance.yahoo.com2 min
OCT 20
$RAPPMedAI 8/10

Guggenheim raises Rapport Therapeutics price target to $70 on trial data

Guggenheim raised its price target on Rapport Therapeutics (RAPP) to $70 from $65, citing positive Phase 2 trial results for bipolar mania. The trial met primary and secondary endpoints, with a 3.1-point placebo-adjusted YMRS reduction. Guggenheim increased its success probability to 65% and adjusted its expected launch to 2030. The stock is currently trading at $30.20, with a Strong Buy consensus among analysts.

investing.com1 min
OCT 20
$RAPPHighAI 8/10

Truist reiterates Rapport Therapeutics stock rating on trial data

Truist Securities reiterated a Buy rating and $56.00 price target for Rapport Therapeutics (RAPP) after positive clinical trial results for RAP-219 in bipolar mania. The stock is currently trading at $29.74, with a Wall Street consensus of Strong Buy and price targets ranging from $50 to $80. Analysts noted consistent efficacy, a clean safety profile, and planned Phase 3 enhancements. The company maintains a strong financial position with a current ratio of 15.72.

investing.com2 min
OCT 20
$RAPPHighAI 8/10

TD Cowen reiterates Buy on Rapport Therapeutics stock after trial

TD Cowen reiterated a Buy rating on Rapport Therapeutics (RAPP) after positive Phase II trial results for RAP-219 in bipolar mania. The trial met primary and secondary endpoints, with a 3.1 point placebo-adjusted improvement on the Young Mania Rating Scale. TD Cowen estimates peak sales of $2.9 billion for RAP-219 and values RAPP at $60 per share, citing strong financial health and pipeline potential.

investing.com2 min